(Q45407829)

English

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

scientific article published on 11 January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy (English)

1 reference

Europe PubMed Central

14 December 2017

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

Andrew James McMichael

8

object named as

Andrew McMichael

1 reference

Europe PubMed Central

14 December 2017

1

object named as

Lucy Dorrell

1 reference

Europe PubMed Central

14 December 2017

author name string

Patricia Williams

2

1 reference

Europe PubMed Central

14 December 2017

Annie Suttill

3

1 reference

Europe PubMed Central

14 December 2017

Denise Brown

4

1 reference

Europe PubMed Central

14 December 2017

Joanna Roberts

5

1 reference

Europe PubMed Central

14 December 2017

Christopher Conlon

6

1 reference

Europe PubMed Central

14 December 2017

Tomás Hanke

7

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

11 January 2007

1 reference

Europe PubMed Central

14 December 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

14 December 2017

25

1 reference

Europe PubMed Central

14 December 2017

17

1 reference

Europe PubMed Central

14 December 2017

3277-3283

1 reference

Europe PubMed Central

14 December 2017

Therapeutic immunization strategies for the control of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Modified vaccinia virus Ankara induces moderate activation of human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Unintended Smallpox Vaccination of HIV-1--Infected Individuals in the United States Military

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Immune reconstitution in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Activation of virus replication after vaccination of HIV-1-infected individuals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Immune activation and virologic response to immunization in recent HIV type 1 seroconverters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.005

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.01.005

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45407829&oldid=2076664820"